Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: RANBAXY PHARMACEUTICALS (PTY) LTD, 14 LAUTRE ROAD, STORMILL EXT. 1, ROODEPOORT, 1724, SOUTH AFRICA
Category and Class: A.2.3 Barbiturates
ATC Code: N03AA02 (antiepileptics, barbiturates and derivatives).
SEDABARB is a long-acting barbiturate, which because of its depressant effect on the motor cortex, is used in the treatment of epilepsy.
Phenobarbitone is about 45 to 60% bound to plasma proteins and is only partly metabolised in the liver. About 25% of a dose is excreted in the urine unchanged at normal urinary pH.
The plasma half-life is about 75 to 120 hours in adults but is greatly prolonged in neonates, and shorter (about 21 to 7 5 hours) in children.
Phenobarbitone kinetics show considerable interindividual variation. Monitoring of plasma concentrations has been performed as an aid in assessing control and the therapeutic range of plasma-phenobarbitone has been quoted as 15 to 40 micrograms/mL or around 60 to 180 micromoles/litre.
Phenobarbitone crosses the placental barrier and is distributed into breast milk.
The pharmacokinetics of phenobarbitone are affected if given with other antiepileptics.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
